ADRB2 and cancer: This effect has primarily been attributed to inhibition of β2AR signalling as the survival benefit appears to be lost in patients taking β1‐selective‐β‐blockers, supporting the ability of non‐selective β‐blockers to reverse the immunosuppressive, cancer‐promoting phenotype induced by βAR signalling [36].